STOCKHOLM, Sweden; and Vancouver, Canada September 10, 2012: The Centre for Drug Research and Development (CDRD) is pleased to announce that they have signed a Memorandum of Understanding with the Karolinska Institutet to facilitate drug development research collaborations between Canadian and Swedish researchers from the two organizations.
This MoU represents the shared understanding between Karolinska Institutet and CDRD that greater collaboration and innovation is required in order to develop new medical therapeutics that will benefit the global community. Karolinska Institutet and CDRD will partner on research projects and workshops in a wide range of therapeutic areas, as well as exchange programs to augment specialized drug development training opportunities.
CDRD and Karolinska Institutet have already begun to identify mutual areas of interest and explore specific opportunities under this agreement – sharing information and ideas on potential joint research projects directed towards the development of new medical therapeutics to benefit people across the world.
“CDRD continues to expand our network of world-leading affiliated institutions around the globe, and we are extremely pleased to be entering into this agreement with Karolinska Institutet, one of Europe’s pre-eminent medical universities,” said Karimah Es Sabar, President and CEO of CDRD. “Both our organizations recognize the many shared benefits of international alliances – including the sharing of knowledge and accelerating the development of much-needed medical therapeutics.”
“At Karolinska Institutet, we are very enthusiastic about this agreement with CDRD. It is important to us to build and leverage international networks in order to be on the frontier of research, education, and innovation – and our overall relationship with Canada has in recent years grown very strong.” said Dr. Ola Hermanson, associate professor in neuroscience and scientific coordinator for relations with Canada at Karolinska Institutet. “Now building this subsequent relationship with CDRD is of particular value due to the Centre’s unique structure and high profile. We are confident that this is the start of a strong and synergistic collaboration that will yield novel technologies and treatments for diseases with unmet medical needs.”
About Karolinska Institutet
Karolinska Institutet is one of the world’s leading medical universities. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. Over 350 students take their PhD degree each year at Karolinska Institutet, after studies corresponding to four years of full-time study. Many of Karolinska Institutet’s doctoral students have taken their first level education abroad. International collaboration increases the quality of education and research and creates unique opportunities for students to establish contact with other research environments. With a close relationship to the clinical milieu, a world-leading infrastructure and a strong financial situation, Karolinska Institutet has excellent prerequisites for sustaining and developing research and education of highest quality.” For more information, please visit: www.ki.se
The Centre for Drug Research and Development (CDRD) is a national not-for-profit drug development and commercialization centre headquartered in Vancouver, Canada that provides expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. In doing so, we de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector — successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). For more information, please visit: www.cdrd.ca
For additional information, please contact:
Centre for Drug Research and Development
(604) 221-7750 x 223
Press officer, international media relations
+46 8 524 860 66